CH399434A - Process for the preparation of therapeutically active sulfonylureas - Google Patents

Process for the preparation of therapeutically active sulfonylureas

Info

Publication number
CH399434A
CH399434A CH209860A CH209860A CH399434A CH 399434 A CH399434 A CH 399434A CH 209860 A CH209860 A CH 209860A CH 209860 A CH209860 A CH 209860A CH 399434 A CH399434 A CH 399434A
Authority
CH
Switzerland
Prior art keywords
isocyanate
solution
formula
sulfonamide
urea
Prior art date
Application number
CH209860A
Other languages
German (de)
Inventor
Cannon Cheney Lee
Gaston Perron Yvon
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of CH399434A publication Critical patent/CH399434A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52Y being a hetero atom
    • C07C311/54Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms

Description

  

  
 



  Verfahren zur Herstellung therapeutisch wirksamer Sulfonylharnstoffe
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung therapeutisch wirksamer Verbindungen, welche sich insbesondere als hypoglykämische Medikamente zur Verabreichung an gewisse Diabetiker eignen und der Formel
EMI1.1     
 entsprechen, worin R ein unsubstituierter oder substituierter Alkyl-,   Aryl-,    Aralkyl- oder   Cyclo-    alkylrest mit höchstens 8 Kohlenstoffatomen ist, welches dadurch gekennzeichnet ist, dass man die Verbindung der Formel
EMI1.2     
 mit einem Isocyanat der Formel R-N=C=O umsetzt oder einen   N-(p-Trifluormethyl-benzolsulfonyl)-    carbaminsäureester mit einem Amin der Formel R-NH2 kondensiert.



   R kann die folgende Bedeutung haben: n-Propyl, n-Butyl, Cyclohexyl, Pyridyläthyl, Pyridyl, Morpholino, Morpholinoäthyl und Morpholinopropyl.



   Verbindungen, welche sich nach dem erfindungsgemässen Verfahren herstellen lassen, sind z. B. die folgenden:    N-n-Propyl-N'-(p-trifluormethyl-benzolsulfonyl)-    harnstoff (Smp. 149 bis 1500);    N-n-Butyl-N'-(p-trifluormethylwbenzolsulfonyl)-    harnstoff (Smp. 133 bis 1350);    N-Cyclohexyl-N'-(p-trifluormethyl-benzolsulfonyl)-    harnstoff (Smp. 181 bis 1820);   
N-[2-Pyridyl-(2)-äthyl]-N'-(p-trifluormethyl- benzolsulfonyl)-harnstoff     (Smp. 166 bis 1670);    N- (3 -Morpholino-propyl) -N'-(p-trifluormethyl    benzolsufonyl)-harnstoff  (Smp. 197 bis 1990) und   
N-(2-Morpholinoäthyi)-N'-(p-trifluormethyl- benzolsulfonyl)-harnstoff     (Smp. 196 bis 1970).



   Das neue, bei dem erfindungsgemässen Verfahren als Ausgangsprodukt dienende 4-Trifluormethylbenzolsulfonamid kann durch eine Reaktionsserie hergestellt werden, welche ausgeht von   $Chlor-3-      nitro-benzyltrifiuorid,    welches mit Natriumsulfit zum bis-   (2-Nliro-4trifluormethyl-phenyl)-disulfid    umgesetzt wird. Die letztere Verbindung kann mit Chlor in Eisessig aufgespalten   werden    und bildet dabei 2 Moleküle   2-Nitro-4-trifluormethyl-benzol.sulfonyl-    chlorid.

   Wird die letztere Verbindung   mit    wasserfreiem Ammoniak in der Kälte umgesetzt, so bildet sich   2-Nitro- 4 trifluormethyl-benzolsulfonamid.    In diesem Produkt kann man die Nitrogruppe zur Aminogruppe reduzieren, wobei das 2-Amino-4trifluormethylbenzolsulfonamid entsteht. Spaltet man daraus die Aminogruppe ab, so bildet sich das genannte Ausgangsprodukt. Die Reaktion wird mit Vorteil so durchgeführt, dass man die Reaktanten langsam zu einer Lösung des Sulfonamids zufügt und das Reaktionsgemenge mehrere Stunden lang bei Zimmertemperatur stehenlässt. Das entstandene kristalline Produkt kann ausgefällt werden durch Zugabe der Reaktionsmischung zu einem grossen Volumen wässriger Essigsäure und Abfiltrieren der ausgefallenen Kristalle.

   Nach einer vorzugsweisen Ausführungsform des erfindungsgemässen Verfahrens wird die Umsetzung in Gegenwart eines Formamids durchgeführt.  



   Beispiel 1
Eine Lösung von 4,2 g n-Propylisocyanat (0,05 Mol) in 10 ml Dimethylformamid wird langsam unter gutem Rühren zu einer Lösung von 5,6 g (0,025 Mol) von   4Trifluormethyl-benzolsulfonamid    in 15   ml    Tri äthylamin zugegeben. Nachdem die Zugabe vollendet ist, das heisst nach ungefähr 20 Minuten, wird das Reaktionsgemisch bei Zimmertemperatur während ungefähr 3 Stunden stehengelassen. Das Reaktionsgemenge wird hierauf langsam unter mechanischem Rühren zu 150 ml einer   20 % igen    wässrigen Essigsäurelösung zugefügt. Die weisse feste Substanz, welche ausfällt, wird abfiltriert, mit kaltem Wasser gewaschen und hierauf in 75 ml einer 5%igen wässrigen Natriumcarbonatlösung aufgelöst. Die erhaltene Lösung wird filtriert, um geringfügige Anteile unlöslichen Materials abzutrennen.

   Anschliessend wird das Produkt erneut gefällt durch tropfenweise Zugabe der klaren Lösung zu 150 ml einer   20% eigen    wässrigen Essigsäurelösung. Das fast weisse kristalline Präzipitat wird abfiltriert, mit kaltem Wasser gewaschen und aus Isopropanol-Wasser umkristallisiert.



  Das rein weisse Produkt im Gewicht von 6,5 g   (84%    der theoretischen Ausbeute) hat einen Smp. von 149 bis 1500.



  Analyse:
Berechnet für   C11H15F3N2O3 5     (Molekulargewicht   310,29):   
C   42,58%    H   4,19%    N   9,03%   
Gefunden: C   43,88%    H   4,62%    N   8,93%   
Nachdem die Analysenprobe erneut aus Benzol umkristallisiert worden war, betrug der Smp. 149 bis 1500, und die Analyse ergab C   43,88%;    H   4,54%;    N   8,92%.    Die Infrarotanalyse ergab ebenfalls das Produkt, das als   N-Propyl-N'-(p-trifluormethyl-    benzolsulfonyl)-harnstoff anzusprechen ist.



   Die erhaltene Verbindung erwies sich nach oraler Verabreichung als von geringer Toxizität und als wirksames hypoglykämisches Agens, welches durch den Gastrointestinaltrakt rasch absorbiert wird.



   Beispiel 2
Eine Lösung von 14,85 g (0,15 Mol) von n-Butylisocyanat in 25   nil    Dimethylformamid wird tropfenweise während 30 Minuten zu einer Lösung von 22,5 g (0,1 Mol) von 4-Trifluormethyl-benzolsulfonamid in 60 ml Triäthylamin unter Rühren zugegeben. Das Reaktionsgemenge wird über Nacht bei Zimmertemperatur stehengelassen.



   Nach dieser Zeit wird die Reaktionsmischung langsam zu 60 ml einer   20% eigen    wässrigen Essigsäurelösung unter Rühren zugefügt. Die ausgefallene feste Substanz wird abfiltriert, mit kaltem Wasser gewaschen und unter Rühren aufgelöst in einer   5% gen    wässrigen Natriumcarbonatlösung (400 ml).



  Nachdem sich das Produkt vollständig gelöst hat, wird Aktivkohle zur Entfärbung der Lösung zuge geben. Nachdem 15 Minuten lang gerührt worden ist, wird die Aktivkohle abfiltriert und die klare farblose Lösung tropfenweise zu 700 ml einer 20 % igen wässrigen Essigsäurelösung unter Rühren zugefügt. Das farblose kristalline Produkt, welches ausfällt, wird abfiltriert, mit kaltem Wasser gewaschen und aus einer wässrigen Isopropanollösung umkristallisiert, wobei 20,0 g   (61%    der theoretischen Ausbeute) des kristallinen N-Butyl-N'-(p-trifluor-   methyl-benzolsulfonyl) -harnstoff    entstehen, welcher bei 133 bis 1350 schmilzt.



  Analyse:
Berechnet für   C12H15F3N2 03S     (Molekulargewicht 324):
C 44,44% H 4,62% N 8,61%
Gefunden: C   44,58%    H   4,71%    N   8,82%   
Das Produkt erweist sich bei oraler Verabreichung als wirksames hypoglykämisches Agens von geringer Toxizität.



   Beispiel 3
Zu 14,9 g (0,05 Mol) Äthylcarbamat des Tri  fluormethyibenzolsulfonamids    wurden auf einmal   12,2    g 2-Pyridyläthylamin in 50   ml    Benzol zugefügt.



  Nach dem Umrühren und Heizen auf einem Dampfbad vervollständigte sich das Auflösen, worauf das Benzol abgetrieben wurde. Nachdem 4 Stunden lang bei 1250 und 0,8 ml Hg geheizt worden und der Rückstand aus Isopropanol/Wasser umkristallisiert worden war, erhielt man 12 g eines Produktes vom Smp. 166 bis 1670. Die Ausbeute des erhaltenen    N-[Pyridyl-(2)-äthyl]-N'-trifluormethyl-benzol    sulfonylharnstoffes betrug   64,4 %    der Theorie.



  Analyse:
Berechnet für   C15H14F3N3O3S     (Molekulargewicht   373,34):   
C   48,30%    H 3,78%
Gefunden: C   48. 58%    H   3,99%   
Beispiel 4
Zu 14,9 g (0,05 Mol) Äthylcarbamat des Tri  fluormethyl-benzolsulfonamids    wurden auf einmal 21,6 g   (90,15    Mol) N-(3-Amino-propyl)-morpholin in 50 ml Benzol zugegeben. Das Gemenge wurde durchgewirbelt und auf dem Wasserbad zur Vervollständigung der Auflösung erwärmt. Das Benzol wurde unter vermindertem Druck abgetrieben und der Rückstand auf 1200 (Badtemperatur) erwärmt und 4 Stunden lang bei 0,5 ml Quecksilberdruck belassen. Der erhaltene Rückstand wurde zweimal aus   Isopropanol/Wasser    umkristallisiert.

   Die Umkristallisation des erhaltenen
N-(3-Morpholino-propyl)-N'-trifluoromethyl benzolsulfonyl-harnstoffes ergab 9,6 gg vom Smp. 197 bis 1999 .  



  Analyse:
Berechnet für C15H20F3N3O4S  (Molekulargewicht   395,4):   
C 45,7% H   4,09%   
Gefunden:
C   44,70%;      45,72%    H 4,90%;   5,11%   
Beispiel 5
Zu 14,9 g (0,05 Mol) Äthylcarbamat des Trifluormethyl-benzolsulfonamids wurden rasch 19,4 g (0,15 Mol) des   N-(2-Amino-äthyl)-morpholins    in 50   ml    Wasser zugefügt. Das Gemenge wurde auf dem Wasserbad erhitzt, bis   vollständige    Auflösung eingetreten war. Das Wasser wurde unter vermindertem Druck abgetrieben und der   Rücktand    auf 1200 4 Stunden lang unter vermindertem Druck (0,5 ml Hg) erwärmt.

   Der Rückstand wurde umkristallisiert aus Isopropanol/Wasser und dann aus   Dioxan/Wasser,    wobei 4,4 g    N-(2-Morpholino-äthyl)-N'-(4-trifluormethyl-    benzolsulfonyl)-harnstoff vom Smp. 196,5 bis 197,50 erhalten wurden.



  Analyse :
Berechnet für: C   44,2%    H 4,75%
Gefunden: C   44,18%    H   4, 58S   
Beispiel 6
Andere   hypogtykämische    wirksame Verbindungen, wie
N-Isopropyl-N'-(p-trifluormethyl-benzolsulfonyl) harnstoff,
N-t-Butyl-N'-(p-trifluormethyl-benzolsulfonyl) harnstoff,    N-Isotutyl-N'-(ptrifluorraethyl-benzols     harnstoff,
N-Amyl-N'-(p-trifluormethyl-benzolsulfonyl) harnstoff,
N-Cyclohexyl-N'-(p-trifluormethyl-benzol sulfonyl)-harnstoff und
N-Isopropyl-N'-(p-trifluormethyl-benzolsulfonyl) harnstoff lassen sich nach den in den Beispielen 1 und 2 beschriebenen Verfahrensweisen herstellen, wobei
Isopropylisocyanat, t-Butylisocyanat,
Isobutylisocyanat, Amylisocyanat,

  
Cyclohexylisocyanat und Isoamylisocyanat anstelle der in den Beispielen 1 und 2 genannten n-Propylisocyanat und n-Butylisocyanat verwendet werden.   



  
 



  Process for the preparation of therapeutically active sulfonylureas
The present invention relates to a process for the preparation of therapeutically active compounds which are particularly suitable as hypoglycemic medicaments for administration to certain diabetics and of the formula
EMI1.1
 correspond, in which R is an unsubstituted or substituted alkyl, aryl, aralkyl or cycloalkyl radical with at most 8 carbon atoms, which is characterized in that the compound of the formula
EMI1.2
 with an isocyanate of the formula R-N = C = O or an N- (p-trifluoromethylbenzenesulfonyl) carbamic acid ester is condensed with an amine of the formula R-NH2.



   R can have the following meanings: n-propyl, n-butyl, cyclohexyl, pyridylethyl, pyridyl, morpholino, morpholinoethyl and morpholinopropyl.



   Compounds which can be prepared by the process according to the invention are, for. B. the following: N-n-propyl-N '- (p-trifluoromethyl-benzenesulfonyl) - urea (m.p. 149 to 1500); N-n-butyl-N '- (p-trifluoromethylwbenzenesulfonyl) urea (m.p. 133 to 1350); N-Cyclohexyl-N '- (p-trifluoromethyl-benzenesulfonyl) -urea (m.p. 181 to 1820);
N- [2-pyridyl- (2) -ethyl] -N '- (p-trifluoromethylbenzenesulfonyl) urea (m.p. 166 to 1670); N- (3 -morpholino-propyl) -N '- (p-trifluoromethyl benzenesufonyl) urea (m.p. 197 to 1990) and
N- (2-Morpholinoäthyi) -N '- (p-trifluoromethylbenzenesulfonyl) -urea (mp. 196 to 1970).



   The new 4-trifluoromethylbenzenesulfonamide, which is used as the starting material in the process according to the invention, can be prepared by a series of reactions which start from chloro-3-nitro-benzyl trifluoride, which is reacted with sodium sulfite to form bis (2-niro-4trifluoromethylphenyl) disulfide becomes. The latter compound can be split up with chlorine in glacial acetic acid and forms 2 molecules of 2-nitro-4-trifluoromethyl-benzene-sulfonyl chloride.

   If the latter compound is reacted with anhydrous ammonia in the cold, 2-nitro-4-trifluoromethylbenzenesulfonamide is formed. In this product, the nitro group can be reduced to an amino group, which results in 2-amino-4trifluoromethylbenzenesulfonamide. If the amino group is split off from it, the starting product mentioned is formed. The reaction is advantageously carried out in such a way that the reactants are slowly added to a solution of the sulfonamide and the reaction mixture is left to stand for several hours at room temperature. The resulting crystalline product can be precipitated by adding the reaction mixture to a large volume of aqueous acetic acid and filtering off the precipitated crystals.

   In a preferred embodiment of the process according to the invention, the reaction is carried out in the presence of a formamide.



   example 1
A solution of 4.2 g of n-propyl isocyanate (0.05 mol) in 10 ml of dimethylformamide is slowly added with good stirring to a solution of 5.6 g (0.025 mol) of 4trifluoromethylbenzenesulfonamide in 15 ml of triethylamine. After the addition is complete, that is, after about 20 minutes, the reaction mixture is left to stand at room temperature for about 3 hours. The reaction mixture is then slowly added to 150 ml of a 20% aqueous acetic acid solution with mechanical stirring. The white solid substance which precipitates is filtered off, washed with cold water and then dissolved in 75 ml of a 5% strength aqueous sodium carbonate solution. The resulting solution is filtered to remove minor amounts of insoluble material.

   The product is then reprecipitated by adding the clear solution dropwise to 150 ml of a 20% aqueous acetic acid solution. The almost white crystalline precipitate is filtered off, washed with cold water and recrystallized from isopropanol-water.



  The pure white product weighing 6.5 g (84% of the theoretical yield) has a melting point of 149 to 1500.



  Analysis:
Calculated for C11H15F3N2O3 5 (molecular weight 310.29):
C 42.58% H 4.19% N 9.03%
Found: C 43.88% H 4.62% N 8.93%
After the analytical sample was recrystallized again from benzene, the m.p. was 149 to 1500, and the analysis showed C 43.88%; H 4.54%; N 8.92%. The infrared analysis also gave the product, which can be addressed as N-propyl-N '- (p-trifluoromethylbenzenesulfonyl) urea.



   The obtained compound was found to be of low toxicity after oral administration and to be an effective hypoglycemic agent which is rapidly absorbed through the gastrointestinal tract.



   Example 2
A solution of 14.85 g (0.15 mol) of n-butyl isocyanate in 25 nil dimethylformamide is added dropwise over 30 minutes to a solution of 22.5 g (0.1 mol) of 4-trifluoromethylbenzenesulfonamide in 60 ml of triethylamine added with stirring. The reaction mixture is left to stand overnight at room temperature.



   After this time, the reaction mixture is slowly added to 60 ml of a 20% aqueous acetic acid solution while stirring. The precipitated solid substance is filtered off, washed with cold water and dissolved with stirring in a 5% aqueous sodium carbonate solution (400 ml).



  After the product has completely dissolved, activated charcoal is added to decolorize the solution. After stirring for 15 minutes, the activated carbon is filtered off and the clear colorless solution is added dropwise to 700 ml of a 20% aqueous acetic acid solution with stirring. The colorless crystalline product which precipitates is filtered off, washed with cold water and recrystallized from an aqueous isopropanol solution, whereby 20.0 g (61% of the theoretical yield) of the crystalline N-butyl-N '- (p-trifluoromethyl- benzenesulfonyl) urea is formed, which melts at 133 to 1350.



  Analysis:
Calculated for C12H15F3N2 03S (molecular weight 324):
C 44.44% H 4.62% N 8.61%
Found: C 44.58% H 4.71% N 8.82%
The product is shown to be an effective hypoglycemic agent of low toxicity when administered orally.



   Example 3
12.2 g of 2-pyridylethylamine in 50 ml of benzene were added all at once to 14.9 g (0.05 mol) of ethyl carbamate of trifluoromethylbenzene sulfonamide.



  After stirring and heating on a steam bath, dissolution was complete and the benzene was driven off. After heating for 4 hours at 1250 and 0.8 ml of Hg and the residue had been recrystallized from isopropanol / water, 12 g of a product with a melting point of 166 to 1670 were obtained. The yield of the N- [pyridyl- (2) obtained ethyl] -N'-trifluoromethyl-benzene sulfonylurea was 64.4% of theory.



  Analysis:
Calculated for C15H14F3N3O3S (molecular weight 373.34):
C 48.30% H 3.78%
Found: C 48.58% H 3.99%
Example 4
21.6 g (90.15 mol) of N- (3-aminopropyl) -morpholine in 50 ml of benzene were added all at once to 14.9 g (0.05 mol) of ethyl carbamate of trifluoromethylbenzenesulfonamide. The mixture was swirled and warmed on the water bath to complete dissolution. The benzene was driven off under reduced pressure and the residue was heated to 1200 (bath temperature) and left at 0.5 ml of mercury pressure for 4 hours. The residue obtained was recrystallized twice from isopropanol / water.

   The recrystallization of the obtained
N- (3-morpholino-propyl) -N'-trifluoromethyl benzenesulfonyl urea gave 9.6 gg from m.p. 197 to 1999.



  Analysis:
Calculated for C15H20F3N3O4S (molecular weight 395.4):
C 45.7% H 4.09%
Found:
C 44.70%; 45.72% H 4.90%; 5.11%
Example 5
19.4 g (0.15 mol) of N- (2-amino-ethyl) -morpholine in 50 ml of water were quickly added to 14.9 g (0.05 mol) of ethyl carbamate of trifluoromethylbenzenesulfonamide. The mixture was heated on the water bath until complete dissolution had occurred. The water was removed under reduced pressure and the residue was heated to 1200 for 4 hours under reduced pressure (0.5 ml Hg).

   The residue was recrystallized from isopropanol / water and then from dioxane / water, with 4.4 g of N- (2-morpholino-ethyl) -N '- (4-trifluoromethylbenzenesulfonyl) urea with a melting point of 196.5 to 197 .50 were obtained.



  Analysis:
Calculated for: C 44.2% H 4.75%
Found: C, 44.18%, H 4, 58S
Example 6
Other hypoglycaemic compounds such as
N-isopropyl-N '- (p-trifluoromethyl-benzenesulfonyl) urea,
N-t-Butyl-N '- (p-trifluoromethyl-benzenesulfonyl) urea, N-isotutyl-N' - (ptrifluorraethyl-benzenesurea,
N-Amyl-N '- (p-trifluoromethyl-benzenesulfonyl) urea,
N-Cyclohexyl-N '- (p-trifluoromethyl-benzene sulfonyl) -urea and
N-Isopropyl-N '- (p-trifluoromethyl-benzenesulfonyl) urea can be prepared according to the procedures described in Examples 1 and 2, wherein
Isopropyl isocyanate, t-butyl isocyanate,
Isobutyl isocyanate, amyl isocyanate,

  
Cyclohexyl isocyanate and isoamyl isocyanate can be used instead of the n-propyl isocyanate and n-butyl isocyanate mentioned in Examples 1 and 2.

 

Claims (1)

PATENTANSPRUCH Verfahren zur Herstellung von therapeutisch wirksamen Verbindungen der Formel EMI3.1 worin R ein unsubstituierter oder substituierter Alkyl-, Aryl-, Aralkyl- oder Cycloalkylrest mit höchstens 8 Kohlenstoffatomen ist, dadurch gekennzeichnet, dass man das Sulfonamid der Formel EMI3.2 mit einem Isocyanat der Formel R-N=C=O umsetzt oder einen N-(p-Trifluormethyl-benzolsulfonyl)- carbaminsäureester mit einem Amin der Formel R-NH2 kondensiert. PATENT CLAIM Process for the preparation of therapeutically active compounds of the formula EMI3.1 wherein R is an unsubstituted or substituted alkyl, aryl, aralkyl or cycloalkyl radical with at most 8 carbon atoms, characterized in that the sulfonamide of the formula EMI3.2 with an isocyanate of the formula R-N = C = O or an N- (p-trifluoromethylbenzenesulfonyl) carbamic acid ester is condensed with an amine of the formula R-NH2. UNTERANSPRÜCHE 1. Verfahren nach Patentanspruch, dadurch gekennzeichnet, dass das Sulfonamid während einer Zeitdauer von 1/2 bis 24 Stunden mit dem Isocyanat zur Reaktion gebracht wird. SUBCLAIMS 1. The method according to claim, characterized in that the sulfonamide is reacted with the isocyanate for a period of 1/2 to 24 hours. 2. Verfahren nach Patentanspruch, dadurch gekennzeichnet, dass n-Propylisocyanat langsam zu einer Lösung des Sulfonamids zugegeben und das Gemisch bei Zimmertemperatur mehrere Stunden lang reagieren gelassen wird. 2. The method according to claim, characterized in that n-propyl isocyanate is slowly added to a solution of the sulfonamide and the mixture is allowed to react at room temperature for several hours. 3. Verfahren nach Patentanspruch, dadurch gekennzeichnet, dass eine Lösung von n-Butylisocyanat in Dimethylformamid langsam zu einer Lösung des Sulfonamids zugegeben und das Gemisch mehrere Stunden lang stehengelassen wird. 3. The method according to claim, characterized in that a solution of n-butyl isocyanate in dimethylformamide is slowly added to a solution of the sulfonamide and the mixture is left to stand for several hours.
CH209860A 1959-02-24 1960-02-24 Process for the preparation of therapeutically active sulfonylureas CH399434A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79483259A 1959-02-24 1959-02-24

Publications (1)

Publication Number Publication Date
CH399434A true CH399434A (en) 1965-09-30

Family

ID=25163812

Family Applications (2)

Application Number Title Priority Date Filing Date
CH442865A CH403749A (en) 1959-02-24 1960-02-24 Process for the preparation of 1-cyclohexyl-3- (p-trifluoromethyl-benzenesulfonyl) -urea
CH209860A CH399434A (en) 1959-02-24 1960-02-24 Process for the preparation of therapeutically active sulfonylureas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CH442865A CH403749A (en) 1959-02-24 1960-02-24 Process for the preparation of 1-cyclohexyl-3- (p-trifluoromethyl-benzenesulfonyl) -urea

Country Status (5)

Country Link
CH (2) CH403749A (en)
ES (1) ES256000A1 (en)
FR (1) FR611M (en)
GB (2) GB899583A (en)
SE (1) SE302964B (en)

Also Published As

Publication number Publication date
CH403749A (en) 1965-12-15
FR611M (en) 1961-06-19
SE302964B (en) 1968-08-12
GB899584A (en) 1962-06-27
ES256000A1 (en) 1960-09-01
GB899583A (en) 1962-06-27

Similar Documents

Publication Publication Date Title
DE1543564C3 (en) Benzenesulfonylureas, processes for their preparation and pharmaceutical preparations containing them
CH399434A (en) Process for the preparation of therapeutically active sulfonylureas
DE1161905B (en) Process for the production of new condensation products of tetrameric cyanogen halogen
DE1201337B (en) Process for the preparation of benzene sulfonylureas
DE2256979C3 (en) Process for the preparation of benzenesulfonylureas
AT220626B (en) Process for the preparation of new benzenesulfonylureas
DE1174306B (en) Process for the preparation of sulfonylureas
AT201067B (en) Process for the preparation of new N'-substituted N-arylsulfonylureas
DE2157607C3 (en) Sulphonylureas, processes for their production and pharmaceutical preparations containing them
DE974062C (en) Process for the preparation of new benzenesulfonylureas
DE1518895C3 (en) Benzenesulfonylureas, process for their preparation and their use
CH374984A (en) Process for the preparation of benzenesulfonylureas
AT162955B (en) Process for the preparation of new sulfonamide derivatives
AT201608B (en) Process for the production of new sulfonylureas
AT203510B (en) Process for the production of new sulfonylureas
DE1003716B (en) Process for the preparation of new benzenesulfonylureas
AT233584B (en) Process for the production of new hydrindene sulfonylureas
AT221100B (en) Process for the preparation of new sulfonylureas
AT200583B (en) Process for the production of new sulfonyl urethanes
AT234685B (en) Process for the preparation of new 3-phenyl-sydnonimines
DE963058C (en) Process for the preparation of sulfonamides containing urea groups
AT248452B (en) Process for the preparation of new benzenesulfonylcyclohexylureas
AT226725B (en) Process for the production of new sulfonylureas
DE1183496B (en) Process for the preparation of N- (p-trifluoromethylbenzenesulfonyl) -N'-cyclohexylurea
DE1139507B (en) Process for the preparation of N'-substituted N-thiophenesulfonyl ureas